Kala Pharmaceuticals Inc. (KALA)
Kala Pharmaceuticals Statistics
Share Statistics
Kala Pharmaceuticals has 6.45M shares outstanding. The number of shares has increased by 116.27% in one year.
| Shares Outstanding | 6.45M |
| Shares Change (YoY) | 116.27% |
| Shares Change (QoQ) | 32.13% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 5.31M |
| Failed to Deliver (FTD) Shares | 188 |
| FTD / Avg. Volume | 0.29% |
Short Selling Information
The latest short interest is 282.74K, so 4.64% of the outstanding shares have been sold short.
| Short Interest | 282.74K |
| Short % of Shares Out | 4.64% |
| Short % of Float | 4.82% |
| Short Ratio (days to cover) | 4.9 |
Valuation Ratios
The PE ratio is -6.84 and the forward PE ratio is -0.92. Kala Pharmaceuticals's PEG ratio is 0.07.
| PE Ratio | -6.84 |
| Forward PE | -0.92 |
| PS Ratio | 0 |
| Forward PS | 1 |
| PB Ratio | 21.36 |
| P/FCF Ratio | -8.97 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kala Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.99.
| Current Ratio | 3.11 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.99 |
| Debt / EBITDA | -0.3 |
| Debt / FCF | -0.41 |
| Interest Coverage | 7.09 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.01M |
| Employee Count | 38 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42% in the last 52 weeks. The beta is -1.72, so Kala Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -1.72 |
| 52-Week Price Change | -42% |
| 50-Day Moving Average | 5.51 |
| 200-Day Moving Average | 6.38 |
| Relative Strength Index (RSI) | 44.89 |
| Average Volume (20 Days) | 65.02K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -40.98M |
| Net Income | -38.51M |
| EBITDA | -40.98M |
| EBIT | -44.29M |
| Earnings Per Share (EPS) | -1.01 |
Balance Sheet
The company has 51.18M in cash and 12.15M in debt, giving a net cash position of 39.03M.
| Cash & Cash Equivalents | 51.18M |
| Total Debt | 12.15M |
| Net Cash | 39.03M |
| Retained Earnings | -667.92M |
| Total Assets | 55.48M |
| Working Capital | 35.84M |
Cash Flow
In the last 12 months, operating cash flow was -29.38M and capital expenditures 0, giving a free cash flow of -29.38M.
| Operating Cash Flow | -29.38M |
| Capital Expenditures | 0 |
| Free Cash Flow | -29.38M |
| FCF Per Share | -0.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KALA is $15, which is 279.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 279.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 21, 2022. It was a backward split with a ratio of 1:50.
| Last Split Date | Oct 21, 2022 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -17.7 |
| Piotroski F-Score | 2 |